tradingkey.logo

Amneal Pharmaceuticals Inc

AMRX
View Detailed Chart

9.810USD

0.000
Close 09/19, 16:00ETQuotes delayed by 15 min
3.08BMarket Cap
912.82P/E TTM

Amneal Pharmaceuticals Inc

9.810

0.000
Intraday
1m
30m
1h
D
W
M
D

Today

0.00%

5 Days

-1.90%

1 Month

+5.14%

6 Months

+12.37%

Year to Date

+23.86%

1 Year

+11.35%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
16 / 175
Overall Ranking
94 / 4720
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
12.000
Target Price
+22.32%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Generics segment includes a retail and institutional portfolio of over 270 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.29% year-on-year.
Overvalued
The company’s latest PE is 944.18, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 283.67M shares, decreasing 10.37% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 17.49M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Generics segment includes a retail and institutional portfolio of over 270 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Ticker SymbolAMRX
CompanyAmneal Pharmaceuticals Inc
CEOMr. Chintu Patel
Websitehttps://amneal.com/
KeyAI